Spago Nanomedical Ab

Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation

Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development

Spago Nanomedical Year-End Report January-December, 2025

Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026

Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue